These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [New drugs; natalizumab]. van Bronswijk H; Dubois EA; van Gerven JM; Cohen AF Ned Tijdschr Geneeskd; 2008 Mar; 152(9):499-500. PubMed ID: 18389881 [TBL] [Abstract][Full Text] [Related]
24. Natalizumab in the treatment of patients with multiple sclerosis: first experience. Mareckova H; Havrdova E; Krasulova E; Vankova Z; Koberová M; Sterzl I Ann N Y Acad Sci; 2007 Sep; 1110():465-73. PubMed ID: 17911462 [TBL] [Abstract][Full Text] [Related]
25. Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy. Berger JR Mult Scler; 2008 Jun; 14(5):708-10. PubMed ID: 18566035 [TBL] [Abstract][Full Text] [Related]
26. Safety profile of Tysabri: international risk management plan. Iaffaldano P; D'Onghia M; Trojano M Neurol Sci; 2009 Oct; 30 Suppl 2():S159-62. PubMed ID: 19882366 [TBL] [Abstract][Full Text] [Related]
27. [Blocking adhesion molecules with natalizumab in multiple sclerosis]. Schreiner B; Kieseier BC; Hartung HP; Hohlfeld R; Wiendl H Nervenarzt; 2005 Aug; 76(8):999-1005. PubMed ID: 15812675 [TBL] [Abstract][Full Text] [Related]
28. Natalizumab for relapsing multiple sclerosis. Chaudhuri A; Behan PO N Engl J Med; 2003 Apr; 348(16):1598-9; author reply 1598-9. PubMed ID: 12700382 [No Abstract] [Full Text] [Related]
29. Natalizumab for relapsing multiple sclerosis. Jeffery DR N Engl J Med; 2006 Jun; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742008 [No Abstract] [Full Text] [Related]
30. Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody. Drugs R D; 2004; 5(2):102-7. PubMed ID: 15293871 [TBL] [Abstract][Full Text] [Related]
31. Assessing disability progression with the Multiple Sclerosis Functional Composite. Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023 [TBL] [Abstract][Full Text] [Related]
32. Phase III clinical trial using daclizumab for relapsing-remitting multiple sclerosis initiated. Expert Rev Clin Immunol; 2010 Jul; 6(4):509. PubMed ID: 20594121 [No Abstract] [Full Text] [Related]
33. [Multiple sclerosis: between wish and reality]. Kümpfel T; Hohlfeld R MMW Fortschr Med; 2005 May; 147 Spec No 2():83-5. PubMed ID: 15968879 [TBL] [Abstract][Full Text] [Related]
34. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Sørensen PS; Jensen PE; Haghikia A; Lundkvist M; Vedeler C; Sellebjerg F; Koch-Henriksen N; Fogdell-Hahn A; Myhr KM; Hillert J; Gold R Mult Scler; 2011 Sep; 17(9):1074-8. PubMed ID: 21511692 [TBL] [Abstract][Full Text] [Related]
35. Natalizumab for relapsing multiple sclerosis. Meyer MA N Engl J Med; 2006 Jun; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742009 [No Abstract] [Full Text] [Related]
37. Course of relapsing-remitting multiple sclerosis before, during and after natalizumab. Kaufman MD; Lee R; Norton HJ Mult Scler; 2011 Apr; 17(4):490-4. PubMed ID: 21135017 [TBL] [Abstract][Full Text] [Related]
38. Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence? Bergamaschi R; Montomoli C Mult Scler; 2009 Dec; 15(12):1532-3. PubMed ID: 20019096 [TBL] [Abstract][Full Text] [Related]